Development of Potential Orphan Drug Therapy of Intravesical Liposomal Tacrolimus for Hemorrhagic Cystitis Due to Increased Local Drug Exposure
Abstract
Purpose:
The potent immunosuppressive effect of systemic tacrolimus is limited by the high incidence of severe adverse effects, including nephrotoxicity and hypertension. Intravesical application of tacrolimus is hindered by its poor aqueous solubility, justifying the search for novel delivery platforms such as liposomes. We evaluated the pharmacokinetics of tacrolimus encapsulated in liposomes (lipo-tacrolimus), which is being developed as a potential orphan drug indication for hemorrhagic cystitis.
Materials and Methods:
A single dose of lipo-tacrolimus was instilled in the bladder with the rat under anesthesia. Also, tacrolimus was instilled intravesically or injected intraperitoneally in other rat groups. The tacrolimus dose was constant in all formulations at 200 μg/ml. At different times blood, urine and bladder samples were collected and stored at −80C until analysis. Tacrolimus levels in samples were analyzed using microparticle enzyme immunoassay II.
Results:
The AUC of lipo-tacrolimus in serum at 0 to 24 hours was significantly lower than that of tacrolimus instillation or injection. Noncompartmental pharmacokinetic data analysis revealed maximum concentration of lipo-tacrolimus and tacrolimus in serum and urine at 1 and at 2 hours, respectively. Urine AUC(0–24) after intravesical administration was significantly higher than in the intraperitoneal group (p <0.05). Bladder tacrolimus AUC(0–24) did not differ significantly between the groups.
Conclusions:
Single dose pharmacokinetics revealed that bladder instillation of liposome encapsulated tacrolimus significantly decreased systemic exposure to instilled tacrolimus as well as vehicle related toxicity. Intravesical liposomal tacrolimus may be a promising approach as an orphan drug indication for hemorrhagic cystitis.
References
- 1 : FK 506-mediated T-cell apoptosis induction. Transplant Proc2001; 33: 2292. Google Scholar
- 2 : Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol2009; 4: 481. Google Scholar
- 3 : Systemic toxicity of tacrolimus given by various routes and the response to dose reduction. Clin Experiment Ophthalmol2005; 33: 53. Google Scholar
- 4 : Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol2008; 54: 932. Google Scholar
- 5 : Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourol Urodyn2011; 30: 421. Google Scholar
- 6 : Hemorrhagic Cystitis. Emedicine2009; . http://emedicine.medscape.com. Updated September 18, 2009. Google Scholar
- 7 : Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery?. J Liposome Res2006; 16: 281. Google Scholar
- 8 : Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv2007; 4: 403. Google Scholar
- 9 : Povidone-iodine liposomes—–an overview. Dermatology1997; 195: 93. Google Scholar
- 10 : New frontiers in intravesical therapies and drug delivery. Eur Urol2006; 50: 1183. Google Scholar
- 11 : Recent advances in intravesical drug/gene delivery. Mol Pharm2006; 3: 369. Google Scholar
- 12 : Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat. Urology2003; 61: 656. Google Scholar
- 13 : Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol2009; 182: 1393. Link, Google Scholar
- 14 : Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol2002; 146: 964. Google Scholar
- 15 : Liposome encapsulated prostaglandin E1 in erectile dysfunction: correlation between in vitro delivery through foreskin and efficacy in patients. Urology1998; 52: 838. Google Scholar
- 16 : MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia2010; 12: 628. Google Scholar
- 17 : Ethanol causes inflammation in the airways by a neurogenic and TRPV1-dependent mechanism. J Pharmacol Exp Ther2004; 309: 1167. Google Scholar
